Materials listed chronologically, beginning with the most recent, and can be found in full at the Web address indicated
“Trump’s Attempt to Shame Drugmakers Shows Medicare Costs Soaring.” Langreth, R. and Edney, A. Bloomberg. May 15, 2018. Available at http://allh.us/pC9q.
“Promoting Competition to Address Pharmaceutical Prices.” Darrow, J. & Kesselheim, A. Health Affairs. March 15, 2018. Available at http://allh.us/8hvp.
“Friction in the Path to Use of Biosimilar Drugs.” Frank, R. Perspective. New England Journal of Medicine. March 1, 2018. Available at http://allh.us/P9Fg.
“Biosimilars: the Cure for Sky-High Drug Prices or a Stake in the Heart of Innovation?” Hoffmann, M. STAT. February 8, 2018. Available at http://allh.us/3yM9.
“Reforming Biopharmaceutical Pricing at Home and Abroad.” The Council of Economic Advisers, Executive Office of the President. February 2018. Available at http://allh.us/GT7y.
“Making Medicines Affordable A National Imperative: Recommendations.” The National Academies of Sciences, Engineering, and Medicine. November 2017. Available at http://allh.us/EQJG.
“Reducing the Hurdles for Complex Generic Drug Development.” Gottlieb, S. FDA Voice. October 2, 2017. Available at http://allh.us/3mBx.
“Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier?” Sarnak, D., Squires, D., Kuzmak, G., and Bishop, S. The Commonwealth Fund. October 2017. Available at http://allh.us/VvWU.
“Understanding the Drivers of Drug Expenditure in the U.S.” Report. PhRMA. September 28, 2017. Available at http://allh.us/B8X7.
“Opportunities to Build Upon Enhanced Competition for Medicines in the Marketplace.” Korn, D. The Catalyst. PhRMA. July 27, 2017. Available at http://allh.us/7vU6.
“Health Affairs Policy Brief: Biosimilars.” Baghdadi, R. et al. July 21, 2017. Available at http://allh.us/8hvp.
“FDA Tackles Drug Competition to Improve Patient Access.” FDA News Release. U.S. Food & Drug Administration. June 27, 2017. Available at http://allh.us/BNq6.
“Drug Prices.” Langreth, R. Bloomberg. June 23, 2017. Available at http://allh.us/8eDn.
“Would Price Transparency For Generic Drugs Lower Costs for Payers and Patients?” Lieberman, S. and Ginsburg, P. The Brookings Institution. June 2017. Available at http://allh.us/7J8E.
“Enabling Competition in Pharmaceutical Markets.” Morton, F. and Boller, L. Hutchins Center Working Papers No. 30. May 2017. Available at http://allh.us/pfDx.
“Biosimilar Cost Savings in the United States.” Mulcahy, A., Hlavka, J., and Case, S. Perspective. RAND Corporation. 2017. Available at http://allh.us/FAG3.
“Understanding Recent Trends in Generic Drug Prices.” Issue Brief. Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. January 27, 2016. Available at http://allh.us/Pebd.
“Biosimilars 101.” PhRMA. November 2015. Available at http://allh.us/wMBq.
“Biosimilar Competition in the United States: Statutory Incentives, Payers, and Pharmacy Benefit Managers.” Falit, B., Singh, S., and Brennan, T. Health Affairs. February 2015. Available at http://allh.us/YhcF.
“Winning with Biosimilars: Opportunities in Global Markets.” Jacoby, R., Smith, E., Wilkins, D., Iyer, D., and Peltre, S. Deloitte. 2015. Available at http://allh.us/jtHf.
